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 ABSTRACT 
 
Ovarian carcinoma is the fifth most common cause of cancer death in Swedish 
women. Patients with advanced-stage disease respond differently to treatment, and the 
clinical outcome is difficult to predict for an individual patient. To increase the knowledge 
about ovarian adenocarcinomas, we aimed to investigate genetic changes relevant to the 
growth and progression of advanced ovarian tumours. We classified the tumours on a 
biological basis to identify potential biomarkers for use as prognostic factors. 
We analyzed the cytogenetic alterations with comparative genomic hybridization 
(CGH) and found significant differences in cytogenetic alterations in relation to survival, 
surgical outcome, and substage. Gain of regions at chromosome 1 and loss of regions at 
chromosome 4, 5, 8, 16, and X were common disparities associated with reduced survival. 
Gene expression analysis with microarray revealed a subgroup of survivors with a 
specific genetic signature that may be associated with less aggressive tumour progression 
or with tumours more sensitive to treatment. Quantitative real-time polymerase chain 
reaction (QPCR) was used to evaluate potential biomarkers and to narrow down the 
number of relevant genes to study at the protein level. Four genes, CLU, ITGB3, CAPG, 
and PRAME were differently expressed in tumours from survivors and tumours from 
deceased patients. We used western blot for semiquantitative analysis of the 
corresponding proteins, and found a significant difference in expression concerning 
survival for all four proteins. 
We performed an external validation of the four potential biomarkers in a new set of 
advanced ovarian adenocarcinomas. This established ITGB3 (Integrin beta 3) as 
significantly differently expressed concerning survival. The loss of ITGB3 expression in 
tumours from deceased patients and high expression in tumours from survivors could be 
used as a biomarker for patients with advanced serous tumours.  
In conclusion, we have found cytogenetic changes and differences in gene and 
protein expressions between advanced ovarian adenocarcinomas from survivors and 
deceased patients. These differences indicate that it is possible to predict the clinical 
outcome with a biological model for ovarian cancer patients. 
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ABBREVIATIONS 
 
BASE bioarray software environment 
BSA bovine serum albumine 
cDNA complementary DNA 
CGH comparative genomic hybridization 
DAPI diamidino-2-phenylindole 
DNA deoxyribonucleic acid 
ECM extracellular matrix 
FDR false discovery rate 
FIGO International Federation of Gynaecology and Obstetrics  
FITC fluorescein isothiocyanate 
HRP horseradish peroxidase 
IHC immunohistochemistry 
LMP low malignant potential 
Mb  mega bases 
mRNA messenger RNA 
NA not available 
PCR polymerase chain reaction 
QPCR quantitative real-time polymerase chain reaction 
RNA ribonucleic acid  
SD standard deviation 
SDS sodium dodecyl sulfate 
TBS Tris buffered saline 
TBS-S TBS containing 0.1% saponin 
TRITC tetramethylrhodamine isothiocyanate 
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1. INTRODUCTION 
 
1.1 Cancer genetics 
 
The genome encodes proteins that control the function, growth, and division of cells. 
Cancer is a disease caused by alterations in the cell genome. Accumulation of different 
mutations enables the cell to proliferate abnormally and starts the tumour growth. The 
number of genetic events required for tumour initiation and development varies between 
different cell types [1]. The changes can be genetic or epigenetic [2]. Genetic events 
include gain/loss of chromosome regions, inversions, translocations, and mutations. 
Epigenetic modifications, such as DNA methylation, could affect the mechanisms that 
control cell cycle regulation. There are three different classes of genes known to be 
involved in carcinogenesis: proto-oncogenes with dominant gain of function, tumour 
suppressor genes with recessive loss of function, and altered DNA repair genes, which 
have an indirect effect causing increased mutation rate. Well-known examples of 
oncogenes activated in cancer are MYC and RAS, and commonly altered suppressor 
genes are TP53 and RB1. The cancer-related genes effect physiological changes in the cell 
and cell environment to promote tumour growth. The physiological changes could be 
self-sufficiency in growth signals or insensitivity to growth-inhibitory signals, which cause 
a continuous cell replication. Other changes are the evasion of programmed cell death 
(apoptosis), limitless replicative potential, and sustained angiogenesis that maintains cell 
survival. Further, the ability of cells to metastasise and invade tissues is affected in tumour 
cells [2]. In most cancer cases, as with breast and ovarian tumours, it is the cells’ ability to 
metastasise and invade vital organs, and thereby affect the organs’ function, that is lethal 
to the patients. 
 
1.2 Ovarian cancer 
 
The normal ovary is an oval structure about 3-5 cm in dimension, and the surface 
epithelium is a monolayer of cells surrounding the external surface. The most common 
ovarian cancer cases arise from the ovarian epithelium, accounting for 90% of the 
malignant cases, and the major subtypes are serous, mucinous, endometroid, clear-cell, 
and undifferentiated carcinomas [3]. The term ovarian cancer usually refers to these cases 
when used without any other qualification. The most common form is serous papillary 
adenocarcinomas, accounting for approximately 50% of all cases (Figure 1) [3]. Elderly 
women are mostly affected; the median age at first diagnosis is 63 years. Risk factors for 
ovarian cancer are family history of ovarian and/or breast cancer, dysfunctions of the 
ovary, and infertility. Pregnancy, lactation, and the use of contraceptives decrease the risk 
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of developing ovarian cancer [4-6]. About 5-10% of all ovarian cancers are assumed to be 
hereditary cases. 
 
1.2.1 Incidence and survival 
 
Ovarian cancer represents about 3.1% of all cancer cases in women in Sweden and is the 
14th most common malignancy in the country [7]. Although the incidence is low, it is the 
fifth most common causes of cancer death in women [8, 9]. The majority of patients are 
diagnosed at an advanced stage, in part due to a long asymptomatic phase, which 
contributes to the poor prognosis of the disease in Sweden and other countries (Figure 1). 
The overall 5-year survival rate is 45% in Sweden. 
 
 
 
Figure 1. Distribution of ovarian cancer cases according to type and stages. (This figure was 
published in [10], copyright Elsevier, (2006)). 
 
1.2.2 Treatment and prognostic factors 
 
For a long time, the only method available to treat ovarian cancer patients was surgery, 
which was complicated before the introduction of modern anaesthetic. Later on, 
radiation, endocrine therapy, and chemotherapy were introduced and significantly 
improved patients’ survival. Today, the main treatment of patients with advanced ovarian 
cancer is surgery followed by chemotherapy. The first line chemotherapy treatment in 
Sweden was changed during 1998 from different platinum-based combinations at 
different centres (farmorubicine, carboplatin and cyclophosphamide in western Sweden) 
to a combination of paclitaxel and carboplatin. The choice of treatment is governed by 
various prognostic factors. One prognostic factor with high relevance is surgical stage. 
Surgical staging according to the International Federation of Gynaecology and Obstetrics 
(FIGO) standards is presented in Box 1. There is a difference in 5-year survival between 
patients with tumours of different stages (Figure 3). There is no method available today to 
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better predict the survival of patients in advanced stages of the disease. The survival rate 
ranges from 47% for patients with stage IIIa tumours to 42%, 33%, and 19% for patients 
with stage IIIb, IIIc, and IV tumours, respectively [10]. The volume of residual tumour 
after primary surgery is also used as a prognostic factor for patients with ovarian cancer. 
Optimal cytoreduction is preferred, since the survival rate for patients with no 
macroscopic residual tumour after primary surgery is 62% compared to 29% for patients 
with macroscopic residual tumour [10]. Other prognostic factors are age, histologic grade, 
and occasionally DNA ploidy and volume of ascites [11]. However, patients with identical 
tumours regarding these prognostic factors may have different clinical outcomes even 
when treated similarly. There is no method available today to correctly predict the survival 
for patients in advanced stages of the disease. Increasing knowledge of variations in 
tumour biology could help to find additional factors, such as molecular genetic markers, 
to improve the clinical outcome for these patients.  
 
 
 
Box 1. 
Stage I – Growth limited to the ovaries.  
Stage II – Growth involving one or both ovaries with 
pelvic extension. 
Stage III - Tumour involving one or both ovaries with 
histologically confirmed peritoneal implants outside the 
pelvis and/or positive retroperitoneal or inguinal 
nodes. Superficial liver metastases equals Stage III. 
Tumour is limited to the true pelvis, but with 
histologically proven malignant extension to small 
bowel or omentum (Figure 2). 
Stage IIIa – Tumour grossly limited to the true 
pelvis, with negative nodes, but with histologically 
confirmed microscopic seeding of abdominal 
peritoneal surfaces, or histologic proven extension to 
small bowel or mesentery. 
Stage IIIb – Tumour of one or both ovaries with 
histologically confirmed implants, peritoneal metastasis 
of abdominal peritoneal surfaces, none exceeding 2 cm 
in diameter; nodes are negative. 
Stage IIIc – Peritoneal metastasis beyond the 
pelvis >2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes. 
Stage IV – Growth involving one or both ovaries with 
distant metastases. 
 
 
 
 
    Figure 2. Stage III ovarian  
   carcinoma (This figure  was  
    published in [10], copyright Elsevier 
   (2006)) 
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Figure 3. Relative survival by FIGO staging. (This figure was published in [10], copyright Elsevier, 
(2006)). 
 
1.2.3 Ovarian cancer genes 
 
Several genes are known to be involved in the development of ovarian cancer. In 
hereditary cases, the most common mutated genes are  the tumour suppressor genes 
BRCA1 and BRCA2, and the DNA repair genes MSH2 and MLH1 [12, 13]. The most 
frequent studied tumour suppressor genes in sporadic cases of ovarian cancer encodes the 
proteins p53 and CDKN2A [14, 15]. Tumour suppressor p53 (17p13) is a transcription 
factor that plays an essential role in cell cycle regulation. It binds as a tetramer and 
activates expression of downstream genes that inhibit growth and/or invasion. It is 
expressed in very low levels in normal cells. However, it is often mutated to a defective 
form, which is highly expressed in cancer cells, and contributes to cell transformation and 
malignancy. The protein CDKN2A (9p21), involved in the RB1 pathway, prevents 
progression through the cell cycle in the G1 phase. 
 
Among the oncogenes involved in sporadic cases of ovarian carcinoma is the gene MYC 
(8q24), a transcription factor involved in cell cycle progression and cellular transformation 
[16]. Further, three genes ERBB2 (17q21), PIK3CA (3q26),  and AKT (14q32) are 
involved in the ERBB2 signalling pathway, which is linked to cell proliferation and 
inhibition of apoptosis [17]. However, several other genes are most probably involved in 
the development and progression of ovarian carcinoma and have to be identified. Ovarian 
cancer refers to a heterogeneous group of cancers, and different genetic events may lie 
behind the evolution of the different types.  
INTRODUCTION 
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1.2.4 Future prognostic biomarkers 
 
The use of biomarkers may contribute to a better prediction of the clinical outcome for 
patients with ovarian adenocarcinoma, and may facilitate the choice of the most optimal 
and individual treatment. Technological advances, such as expression arrays, are rapidly 
evolving new possibilities to detect potential biomarkers. Cytogenetic changes and 
differences in gene and protein expressions may be used to better predict patients’ clinical 
outcomes. Analyses of ovarian tumours of different grades, types, and stages have 
revealed chromosome regions commonly altered in different groups. Gain of 1q, 3q, 8q, 
12p, 19, and 20q and losses of 4q, 5q, 13, 16, 17, and 18 are common genomic regions 
related to tumour progression [18-20]. Among genes and proteins as biomarkers, HE4 is a 
prominent candidate for detection of ovarian cancer [21, 22]. Several genes associated 
with ovarian cancer have been evaluated as prognostic markers for response to treatment, 
including serum levels of p53 and HER2, though, none of them have sufficient predictive 
value in treatment planning  [23-25].  
 
A search in the literature on “ovarian cancer prognostic factors” results in more than a 
thousand citations. The markers studied are active in diverse fields, such as chemotherapy 
resistance (MDR1), angiogenesis (CD34, VEGF), and immune functions (CRP) (reviewed 
in [26]). CRP is a serum protein that is rapidly produced in response to inflammation, and 
elevated levels have been detected in cancer [27]. Serum CRP has been associated with 
overall survival and is a promising candidate as a biomarker for clinical outcome [28]. 
However, other studies did not find CRP as an independent prognostic factor for survival 
[29]. COX-2 is a protein associated with several functions, since it is induced by pro-
inflammatory cytokines, growth factors, and radiation. An increased expression is 
associated with chemotherapy resistance [23]. Further, CA-125 levels are routinely 
monitored in serum from patients with ovarian cancer. A decreasing level generally 
indicates that therapy has been effective, while increasing levels indicates tumour 
recurrence. The use of CA-125 as a prognostic factor for survival has been thoroughly 
investigated in several studies without any definitive conclusion [30, 31]. The use of 
diverse cut-off values and measurements at different endpoints generate contradictive 
results, which causes difficulties in the interpretation of the data. 
 
Although a variety of gene alterations have been identified, no single gene marker can 
reliably predict the response to therapy and outcome. The following potential biomarkers 
are discussed in this thesis: 
 
ITGB3 Integrin beta 3 
Integrin beta 3 (glycoprotein IIIa, CD61) is encoded by the gene ITGB3, located on 
chromosome 17q21.32. Integrins are integral cell-surface glycoproteins composed of an 
alpha chain and a beta chain. A given chain may combine with several partners, resulting 
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in integrins with various functions. The protein ITGB3 associates at the cell surface with 
the alpha V integrin to form the αvβ3 complex on endothelial and tumour cells, 
monocytes, platelets, and osteoclasts. In association with the alpha IIb integrin, ITGB3 
forms the GPIIb/IIIa complex on platelets and megakaryocytes [32]. Integrins are known 
to participate in cell adhesion and work as receptors in cell-surface mediated signalling, 
through binding with different ligands in focal adhesions (Figure 4) [33-35]. Integrins bind 
to the extracellular matrix (ECM) components, such as vitronectin and fibronectin, and 
connect with the cytoplasmic domains to components of the actin cytoskeleton, 
cytoplasmic kinases, GTPases, and transmembrane growth factor receptors  within the 
cell [36, 37]. During ligand binding, the inactive state of integrins is activated by a 
conformational change, and the signalling works both ways, inside-out of the cell and 
outside-in [36, 38]. 
 
 
Figure 4. Model for the regulation of αvβ3 activity. Inactive, non-ligand-binding integrins are 
activated by inside-out signalling events. Remodelling of the actin cytoskeleton and/or ligand 
binding results in clustering of integrins in focal adhesions, resulting in an increased cell adhesion. 
Signal transduction molecules involved in cell survival and proliferation are activated. 
 
Adherent cells must be anchored to the ECM to survive and proliferate. Ligated αvβ3 
activates cell survival pathways and suppresses proapoptotic signalling, while inactive, 
unligated αvβ3 promotes apoptosis [39, 40]. This dependence is generally lost in tumour 
cells [37]. As molecules involved in cell adhesion and cell signalling, integrins have an 
important role in various tumours. Alterations of integrin expressions result in changes in 
cell adhesion, which enhances cells’ capacity to detach from their primary tumour and to 
migrate and invade other tissues.  
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The expression of αvβ3 integrin has been linked to bad prognosis in breast cancer and 
melanoma, but the relation to ovarian tumours is less clear [41, 42]. In a study by 
Carreiras et al. [43], ITGB3 was found in normal ovarian epithelium and highly 
differentiated carcinomas of the ovary, but was lacking in most of the less-differentiated 
tumours. The expression of the β3 subunit in ovarian tumours was also found as 
significantly less frequent in grade 3 than in grade 1–2 tumours, and less expressed in 
peritoneal metastasis compared to primary tumours [44]. On the contrary, the αvβ3 
integrin expression in ovarian tumour samples and expression of αv integrins have been 
linked to ovarian tumour progression [45].  
 
CLU Clusterin 
The gene encoding CLU is located on chromosome 8p21-p12, a region commonly 
deleted in ovarian, prostate, colon, and breast carcinomas [46-49]. The protein CLU is a 
secretory disulphide-linked glycoprotein that is ubiquitously expressed in serum and in 
many tissues, such as testis, ovary, brain, and liver [50-52]. The protein has been 
associated with many functions, partly due to the diverse functions of its ligands [53, 54].  
The diversity of the protein has led to the hypothesis that the different interactions 
depend on a single common function of CLU [55]. Michel et al. [56] described the 
proximal promoter of CLU to be recognised by heat shock transcription factor 1, and 
showed that CLU mRNA expression was induced by heat. This suggested CLU as a 
possible extracellular heat shock protein, and the theory was further established when 
Humphreys et al. demonstrated that CLU had chaperone activity  [57]. Controversially, 
CLU has also been shown to promote apoptosis [58, 59]. This divergent role of the 
protein is probably due to different isoforms, one secreted form (sCLU) and its 
cytoplasmic precursor (cCLU) with chaperone activity involved in tumour progression, 
and one nuclear form (nCLU) with proapoptotic function. 
 
CLU has been investigated in several types of cancer and reported as down-regulated in 
pancreatic adenocarcinoma, prostate cancer, and serous ovarian carcinoma [60-62]. 
Conversely, expression of CLU mRNA or protein have been reported as up-regulated in 
various advanced tumours compared to early or normal tissue, including bladder, 
prostate, and breast cancer [63-65]. Xie et al. [66] found a significant association between 
overexpression of cCLU in ovarian carcinomas compared to normal ovaries, 
cystadenomas, and borderline tumours, and that apoptosis occurred more often in 
tumours expressing normal levels of CLU. Pucci et al. [67] studied CLU in the different 
steps of colon carcinoma progression and discovered a translocation of CLU from the 
nucleus to the cytoplasm during the tumour development. Although CLU expression 
increases in tumours during progression, its role as a biomarker for survival has to be 
clarified. The expression of cCLU has been associated with longer survival in patients 
with lung cancer [68]. However, CLU expression was increased during breast tumour 
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progression, but did not represent a prognostic indicator by uni- or multivariate analysis 
[65].  
 
PRAME Preferentially expressed antigen in melanoma 
The function of PRAME in normal tissue is still unknown, but it encodes an antigen 
recognised by autologous cytolytic T lymphocytes, and its expression is absent or low in 
normal adult tissue, except male germ cells [69]. The gene PRAME, located at 
chromosome region 22q11.22,  is frequently expressed in a variety of cancers, such as 
melanoma and neuroblastoma, and is evaluated as a potential marker for advanced disease 
[69, 70]. In microarray studies, PRAME has been described as up-regulated in malignant 
ovarian tumours when compared with normal ovarian tissue [71-74].  In a study by 
Lancaster et al. [75] PRAME was up-regulated in ovarian cancer samples compared to 
normal ovarian surface epithelium, but did not separate tumours according to survival. 
However, PRAME expression was associated with unfavourable outcome for breast 
cancer patients and indicated as an independent prognostic factor for survival [76]. 
Because of the high expression in several different cancer types and the low or absent 
expression in normal tissues, evaluation of PRAME as a target for immunotherapeutic 
strategies is of great interest [77]. 
 
CAPG Capping protein (actin filament), gelsolin-like 
A non-muscle cell uses its actin filament network to change shape during movement. The 
filament must be dynamic and undergo rapid reorganisation in order to control cell 
motility [78]. CAPG belongs to the gelsolin protein superfamily, a group of proteins that 
control actin organisation and initiate actin filament growth by severing filaments, capping 
filament ends, and nucleating actin assembly [79, 80]. CAPG binds to and blocks the 
barbed ends (+) of actin filaments but does not sever them. It dissociates from the 
filaments either by a decrease of calcium concentration or by an increase of 
phosphatidylinositol 4,5-bisphosphate (PIP2) [81]. By capping the barbed ends of actin 
filaments, the protein contributes to the control of actin-based motility in cells. CAPG is 
localised both to the cytoplasm and the nucleus, unlike the other gelsolin family members, 
which are located to the cytoplasm [82]. 
 
The involvement of CAPG in cancer is not precisely known. An elevated expression of 
CAPG has been detected in cancer cells compared to benign or normal cells in pancreatic 
carcinoma, melanoma, and breast cancer cells [83-85]. Further, elevated levels of CAPG 
trigger cellular invasion, and nuclear CAPG affects the invasive phenotype, but how these 
relationships are regulated is still unknown [86].  
 
TACC1 Transforming acidic coiled-coil containing protein 1 
Down-regulation of TACC1 has been reported for several tumour types, including 
ovarian and breast cancer [87, 88]. The gene is located at chromosome region 8p11, a 
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region frequently deleted in various tumour types, and TACC1 might be one of the 
cancer-related genes of interest in this region [47, 49, 89]. The normal function of TACC1 
is not precisely known, but observations have shown that the protein is concentrated at 
centrosomes during mitosis and may play a role in cytokinesis [90, 91]. Moreover, the 
protein may be involved in the control of mRNA metabolism [88]. In an 
immunohistochemical analysis by Lauffart and colleagues [87], TACC1 expression was 
absent or minimal in 36.9% of the ovarian serous papillary adenocarcinomas, with 
decreasing expression in relation to stage (stage I (85.7%), stage II (72.2%) and stage III 
(64.7%)).  
 
MUC5B Mucin 5 subtype B 
The gene MUC5B is located at chromosome region 11p15.5. The protein it encodes 
belongs to the mucin family of high-molecular-weight glycoproteins found in human 
epithelial cells. MUC5B, a secreted gel forming mucin, has been reported as abnormally 
expressed in several tumour types, such as gastric carcinoma and breast cancer [92, 93]. 
Studies of ovarian cancer have described higher expressions of MUC5B in tumours of low 
malignant potential (LMP) and Grade 1 tumours compared to Grade 2 and 3 tumours 
[94]. In addition, Gilks and colleagues [61] compared LMP tumours and serous 
carcinomas and found that MUC5B was expressed in higher levels in LMP tumours. 
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2 AIMS 
 
We aimed to investigate genetic changes relevant to the growth and progression of 
advanced ovarian tumours. Further, we intended to study the relation of potential 
biomarkers to patients’ survival in order to find possible ways to classify the tumours on a 
biological basis. 
 
The specific aims in this thesis are to 
 
• detect cytogenetic differences in stage III ovarian adenocarcinomas in relation to 
survival, surgical outcome, and tumour substage (paper I); 
 
• detect differences in gene expressions in stage III ovarian adenocarcinomas in relation 
to survival, surgical outcome, and tumour substage (paper II); 
 
• evaluate possible biomarkers for survival at the gene and protein expression levels 
(paper III); and 
 
• perform an external validation of potential biomarkers in a new set of advanced ovarian 
adenocarcinomas (paper IV). 
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3 MATERIAL AND METHODS 
 
3.1 Tumour material 
 
For the research reported in the first three papers, we used a total of 101 stage III serous 
papillary adenocarcinomas of the ovary. The patients were diagnosed between 1993 and 
2000 at Sahlgrenska University Hospital, Gothenburg, Sweden. The tumours were 
removed at primary surgery and stored at -80°C until use. Surgical staging of the tumours 
was performed according to FIGO standards, and patients with no macroscopic residual 
tumour were classified as radically operated. Tumours surgically classified as stage IIIa 
and IIIb were considered as one group. After surgery, patients were treated with a 
combination of farmorubicine, carboplatin, and cyclophosphamide, according to the 
treatment program for gynaecological malignancies in western Sweden from 1993 [95]. 
We considered patients who survived five years or more after the initial diagnosis as 
survivors, and all deceased patients in the study succumbed to cancer. 
 
 
Figure 5. Schematic view of tumour distribution in paper I-IV. 
 
The tumours were used as follows (Figure 5): In the comparative genomic hybridization 
(CGH) study, 98 tumours were analyzed. Microarray was performed on 54 tumours, of 
which 51 were previously used in the CGH study. In paper III, 19 and 43 tumours were 
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analyzed with quantitative real-time polymerase chain reaction (QPCR) and western blot, 
respectively. All these tumours were previously used in the microarray analysis, but the 
number of tumours was reduced due to lack of tumour material in nine samples.  
 
We used 98 tumours in the external validation in paper IV. These tumours were classified 
in the same manner as the above-mentioned tumours. The tumours were collected from 
patients diagnosed between 1993 and 2003 at primary surgery, and after surgery patients 
were treated with platinum-based chemotherapy. Thirty-one tumours were from patients 
treated with a combination of farmorubicine, carboplatin, and cyclophosphamide, and 
these tumours were previously used in the CGH analysis. The remaining 67 patients were 
treated with a combination of paclitaxel and carboplatin, and 30 tumours from these 
patients were analysed with QPCR.  We analysed the protein levels in all 98 tumours with 
western blot. 
 
3.2 Comparative genomic hybridization 
 
CGH is a molecular cytogenetic method that has been widely used in tumour analysis. It 
enables genome-wide screening and detects copy number changes larger than 10 Mbp 
that occur during cancer development. A major advantage of the method is that 
metaphases from solid tumours are not required. Instead, tumour DNA is hybridised to 
normal metaphase chromosomes together with reference DNA to detect copy number 
changes. Today, this method is improved and replaced by array CGH, using BAC clones 
as hybridisation targets instead of metaphase spreads, giving a resolution down to ~ 100 
kbp. CGH has some limitations, for instance it is not possible to detect balanced genetic 
changes, such as translocations and inversions where no copy number changes are 
involved. Furthermore, the sensitivity and specificity of the CGH decrease when tumour 
material is contaminated with normal DNA or presented in small population of 
subclones. 
 
We used CGH to analyze 98 serous ovarian adenocarcinomas. The first two steps in 
CGH analysis are to isolate and label DNA from tumours. We labelled the tumour DNA 
with biotin and normal reference DNA from female lymphocytes with digoxigenin by 
nick translation. Equal amounts of labelled tumour and reference DNA (1μg) were mixed 
together with cot-1 DNA. The cot-1 DNA is used to suppress cross-hybridisation of 
repetitive sequences in the DNA. The mixture was hybridised to normal metaphase 
spreads, which were prepared according to standard protocols using lymphocytes drawn 
from a healthy donor. One of the greatest technical difficulties to overcome in this 
analysis was to obtain high quality metaphase spreads. Several batches were discarded, but 
when we obtained a high quality batch the method could be performed without further 
complications. After three days of incubation, tumour DNA was detected with FITC- 
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avidin (green) and reference DNA with TRITC-antidigoxigenin (red). For identification 
of the chromosomes, the slides were counterstained with DAPI in an antifade solution. 
 
A  
 
 
B 
 
 
 
Figure 6. A) Separate digitalised images of DAPI (grey), FITC (green) and TRITC (red) and a 
combined picture of FITC and TRITC. B) The corresponding tumour profile. 
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Separate digitalised images of FITC, TRITC and DAPI were captured from each 
metaphase spread (Figure 6A). We compared the intensity of the two fluorochromes and 
a corresponding profile was generated for each tumour, showing gains/amplifications 
(green bars) and losses (red bars) along the chromosomes (Figure. 6B). Fluorescence ratio 
above 1.15 was defined as gain and ratio under 0.85 as loss.  
 
CGH-generated profiles from the 98 ovarian tumours were grouped and subgrouped 
according to three different clinical factors: survival (tumours from survivors or tumours 
from deceased patients), surgical outcome (tumours from patients who underwent radical 
surgery or had macroscopic residual tumour) and tumour substage (stage IIIa+b or IIIc). 
The alteration frequencies in chromosome regions in the subgroups were calculated. 
Subsequently, we compared the alteration frequencies in a region between subgroups with 
a hypothesis test, or by chi-square analysis in cases with few tumours or when the 
frequency of alterations was low. A P-value < 0.05 was considered to be statistically 
significant. 
 
3.3 Gene expression array 
 
Gene expression array (microarray) is a technology which enables large-scale expression 
analysis of a cell line or a tissue sample. mRNA extracted from the samples is used to 
synthesise labelled cDNA fragments. These fragments are hybridised to a large number of 
nucleotide sequences bound to a solid surface, such as a glass slide. The expression 
profiles can be used to classify different subsets of tumours with similar properties and to 
identify genes involved in tumour initiation and progression. 
 
In this study, we isolated total RNA from frozen tumours by homogenisation followed by 
extraction with RNeasy mini kit. Since RNA is extremely unstable and degrades quickly, 
we verified the quality of the RNA with Agilent 2100 bioanalyzer and removed samples 
with poor quality before any downstream applications. We labelled the tumour RNA with 
Cy3 and a universal human reference RNA with Cy5. The use of a common reference 
probe allowed us to treat the fluorescent ratios as measurements of the relative expression 
level of each gene across all samples. The probes were hybridised to oligonucleotide 
microarrays containing 27,000 unique probes on a glass slide, provided by SCIBLU 
Microarray Resource Center, Department of Oncology, Lund University, Sweden 
(http://www.lth.se/sciblu/services/dna_microarrays). All arrays used were from the 
same print run to avoid technical differences between slides. 
 
 For analysis and visualisation of the results, the generated raw intensity files were 
transferred to BASE and R (version 2.1.1) used with the package Limma [96, 97]. More 
information about the computer programs is available at http://base.thep.lu.se/, 
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http://www.r-project.org, and http://www.bioconductor.org. The data were processed 
with both R and BASE to obtain relevant numbers. The advantage of using two different 
programs is that the results could be compared. If the results are in concordance, despite 
slightly different methods of analysis, the results are more solid. With R, we computed 
log2(ratio) values and loess normalisation was applied to each array in order to remove 
intensity-dependent effects [98]. The loess normalisation assumes that the log-ratios of all 
measurements will be average to zero within each array, and adjusts the intensity levels 
according to that [98]. Only genes with a valid log2(ratio) value in at least 40 (74%) of the 
54 tumours (16,976 genes) were used in the analysis. 
 
To implement a hierarchical clustering, the gene expression values were transferred to the 
cluster software Hierarchical Clustering Explorer (HCE). Low variable genes with a 
standard deviation (SD) across all samples less than 0.5 or 1 were filtered out. Thus, genes 
with similar expression in all tumours have less influence on the result than differently 
expressed genes. The hierarchical clustering was performed with the linkage methods 
Complete and Average, and the distance measures Euclidean and Pearson correlation 
coefficient in different combinations to determine if the same result was accomplished 
with different tests. 
 
Subsequently, we studied differences between: (1) tumours from survivors and tumours 
from deceased patients, (2) tumours from patients in the subgroup of survivors detected 
by hierarchical clustering and the remaining tumours, (3) tumours from patients with and 
without macroscopic residual tumour left after primary surgery, and (4) stage IIIa+b and 
stage IIIc tumours. Differences in log2(ratio) values between groups were tested for each 
gene using two-sample t tests with a moderated t statistic [97]. P-values were adjusted to 
control the false discovery rate (FDR; i.e., the expected proportion of false positive 
findings among all positive findings). A gene with an FDR-adjusted P < 0.05 and at least a 
twofold change between groups was classified as significantly differently expressed. 
 
3.4 Quantitative real-time polymerase chain reaction 
 
QPCR is a method used to accomplish quantitative measurements of a cDNA fragment. 
The principle is much the same as with conventional PCR. Two oligonucleotide primers 
hybridise to the opposite strands of the target DNA sequence that is amplified. A 
repetitive series of cycles with template denaturation, primer annealing, and extension 
with polymerase gives exponential accumulation of the DNA fragment. With QPCR, 
fluorescence molecules are incorporated to or bind to the DNA. The fluorescence is 
measured for each cycle and the signal is proportional to the initial amount of PCR 
product. A comparison with reference genes gives the relative quantification of the target 
DNA in each sample.  
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In paper III, we performed QPCR on the 19 samples with highest RNA quality from the 
previous microarray analysis. The genes analysed were CLU, ITGB3, TACC1, MUC5B, 
CAPG, PRAME, and TROAP. In paper IV, 30 tumours were used to measure the 
expression of ITGB3, CLU, CAPG, and PRAME. 
 
From each tumour sample total RNA was reverse transcribed in duplicate with a mixture 
of random hexamers and oligo(dT) primers. Each cDNA sample was analysed by real-
time PCR and SYBR Green was used to detect the cDNA. SYBR Green binds to double- 
stranded DNA and the resulting complex emits green light. Signal intensity was measured 
for each cycle. A melt curve analysis was performed after each run to verify specific 
amplification. The efficiency of each QPCR assay was estimated from the slope of a 
standard curve generated from the serial dilution of purified PCR products. The assays 
for CLU and ITGB3 showed PCR efficiencies close to 80%, and for the remaining genes 
90%. For each assay the average Ct value for each tumour sample was converted to 
relative copy numbers and the data were then normalised by the geometric average of the 
2 reference genes GAPDH and β-actin [99]. Statistical differences in mRNA expressions 
between tumours from survivors and tumours from deceased patients were evaluated 
using the Mann-Whitney U test, and a value of P < 0.05 was considered to be significant. 
 
3.5 Western blot 
 
Western blot is a method used to detect and identify proteins with specific antibodies 
directed to the protein of interest. Total amount of protein from a cell can be extracted, 
or fractionated in cytoplasm and nuclear extracts, depending on the detergents used in the 
experiment. The protein homogenate is diluted with SDS loading buffer, giving the 
protein a negative charge. Reducing agents, such as 2-mercaptoethanol, are commonly 
used in the buffer to break the proteins’ disulphide bridges. The proteins are separated by 
size and negative charge with gel electrophoresis. Subsequently, the proteins are 
transferred to a membrane and exposed to the specific antibody that binds to the protein 
of interest. The optical density from each band can be measured and used for 
semiquantitative analysis of the proteins. 
 
In paper III, western blot was performed on 43 tumour samples, and in paper IV 98 
tumours were analysed, each in duplicate. Total protein extracts were prepared in RIPA 
lysis buffer containing proteinase inhibitors. We homogenised the frozen samples with 
RIPA, and determined the protein concentrations to assure equal loading of each tumour 
sample. The samples were diluted in SDS sample buffer with and without 10%  
2-mercaptoethanol and denatured. The unreduced samples (without 2-mercaptoethanol) 
were used to detect ITGB3. Twenty micrograms of total protein was loaded into each 
lane on a gel and then transferred to nitrocellulose membranes. The membranes were 
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blocked overnight at 4°C in 5% non-fat milk in Tris buffered saline (TBS) to reduce 
background signal.  
 
We optimised the amount of primary antibody used to detect CAPG, PRAME, CLU, 
ITGB3, and GAPDH. The primary antibodies were specific and detected one band on 
the membranes, except for CLU. The antibody was specific, but three different isoforms 
of CLU could be detected with the antibody used in our analysis. A cytoplasmic precursor 
CLU (cCLU) appears at 60kDa. This precursor is cleaved into α and β subunits linked 
together by disulfide bonds. The mature sCLU is then glycosylated and the α subunit 
appears as a 40kDa smear after gel electrophoresis, depending on the level of 
glycosylation [50, 67]. The nuclear unglycosylated form of CLU (nCLU) appears as a 
50-55kDa protein and is produced from a splicing variant of the mRNA [100]. 
 
Proteins were visualised by chemiluminescence, using horseradish peroxidase-linked 
(HRP) secondary antibodies, followed by exposure of the membranes to autoradiography 
films. The optical density from each band was measured and used for semiquantitative 
analysis of the proteins. We used an internal reference sample as a standard to avoid 
difference among blots caused by technical variations. The same amount of reference 
sample was loaded on each gel and used to normalise the intensity, and was given the 
value 1 [101]. Statistical differences in protein expressions between tumours from 
survivors and tumours from deceased patients were evaluated using the Mann-Whitney U 
test, and a value of P < 0.05 was considered to be significant. 
 
3.6 Immunohistochemistry 
 
Immunohistochemistry (IHC) is used to localise or quantify proteins in tissue cells with 
antibodies. Thin sections of the tumours are exposed to a specific labelled antibody. 
Visualisation of the antibodies can be accomplished in different ways, such as the use of 
peroxidase or fluorescence staining.  
 
IHC staining was performed to detect if CLU was expressed as nCLU, cCLU, or sCLU, 
and to ensure that tumour cells expressed ITGB3. Fresh-frozen tissues from 43 tumours 
were cryosectioned and the staining procedure was accomplished using DakoCytomation 
EnVision+ HRP. TBS containing 0.1% saponin (TBS-S) was used as buffer solution. 
Slides were blocked with TBS-S containing 3% BSA prior to incubation with CLU 
antibody to reduce background staining. Slides were incubated with primary antibody 
mouse CLU or with mouse monoclonal to ITGB3 diluted in TBS-S containing 1% BSA. 
We used the incubation buffer without primary antibody as negative control and staining 
in endothelial cells as internal positive control for ITGB3. The CLU antibody used was 
the same as in the immunoblotting assay, but the two ITGB3 antibodies used were 
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different, as none of them worked in both applications. The sites of peroxidase binding 
were detected with 3,3'-diaminobenzidine and cells were counterstained with hematoxylin. 
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 4 RESULTS AND DISCUSSION 
 
Ovarian epithelial carcinomas are a heterogeneous group, consisting of tumours with 
different epithelial origin. It is important to use homogeneous tumour groups in studies 
of clinical endpoints to ensure the results are not affected by other factors, e.g., tumour 
stage or histological subtypes. Therefore, only stage III or IV serous papillary ovarian 
adenocarcinoma, which is the most common type of ovarian cancer, was used in our 
analyses.  
 
4.1 Chromosome alterations 
 
Using CGH, we detected 48 regions altered in more than 10% of the tumours. The most 
common alterations in our study were gains of regions in chromosomes 1q, 3q, and 8q 
and losses of 4q, 5q, 8p, 17, and X, which is in concordance with previous studies [19, 
102]. Thirteen tumours did not exhibit any chromosomal aberration, of which eight (17%) 
were from survivors and five (7%) were from deceased patients. The DNA ploidy is 
routinely measured with flow cytometry, and 22 of the 98 tumours were established as 
diploid (data not shown). Nine of those were among the 13 tumours detected as diploid 
with CGH, demonstrating a correlation between the measurements. 
 
The tumours were grouped and subgrouped according to survival, surgical outcome, and 
substage. Chromosome regions were altered differently depending on tumour 
classification and a summary of the results are shown in Figure 7. The alterations 
representing tumours from deceased patients were gain of 1q24-qter and losses of 4p, 
4q31.1-qter, 5q12-q22, 8p, 16q and X. CGH analyses performed on ovarian carcinomas 
are consistent regarding common changes correlated to survival. Gain of chromosome 1, 
3, 7, and 8 and loss of 4, 16, and X are common disparities previously associated with 
reduced survival, which is in concordance with our results [102, 103]. We conclude that 
the chromosomal aberrations we detected may predict a poor clinical outcome for 
patients with stage III serous papillary ovarian adenocarcinomas. However, it might be 
difficult to use chromosomal aberrations as biomarkers in clinical practice. Analysis of 
stage I ovarian adenocarcinomas revealed several altered chromosome regions, suggesting 
that aberrations are early events in tumour progression [104]. Even though findings from 
different studies identify similar chromosome regions, the tumour heterogeneity makes it 
difficult to select a usable specific signature for clinical outcome. CGH, and especially 
array CGH, may be a useful method to identify alterations in more homogeneous 
tumours and hereditary cases of cancers. CGH analysis of heterogeneous tumours, such 
as ovarian adenocarcinomas, might be better used for screening to find regions of interest 
for further investigations. 
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CGH can only yield an indication of the chromosomal regions involved in gains or losses, 
but cannot specify which genes are involved. Losses of the regions in chromosome 4, 8, 
and 16 were common disparities between tumour subgroups in our study, and these 
regions contain several cancer-related genes. However, the resolution of CGH is rather 
low and today other methods, such as array CGH, could be used to more accurately 
predict the number of gene copies. It has been demonstrated that the results from 
conventional CGH and array CGH are consistent (Österberg et al., in manuscript). We 
hypothesised that further molecular analysis, such as gene expression studies, could clarify 
the biological differences within this homogeneous tumour group.  
 
 
Figure 7. Chromosomal regions significantly more altered in the subgroups related to poor 
outcome regarding A) survival (deceased patients), B) surgical outcome (macroscopic residual 
tumour) and C) substage (IIIc tumours). Gains are represented by green bars to the right of the 
chromosomes and losses by red bars to the left. 
 
4.2 Gene expressions 
 
The microarray experiment generated results from 25,802 probes. We started to analyse 
the gene expressions with a hierarchical clustering of our microarray data. There are 
several ways to perform hierarchical clustering and almost as many different results could 
be achieved. This is both a weakness and a strength of the method. It is possible to 
choose the test that gives you the results you want. On the other hand, if the same result 
is accomplished with different tests, the result is more reliable. To implement the 
hierarchical clustering, three different combinations were used that generated similar 
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results in the different tests. The most striking cluster similarity included a group of 12 
tumours (60%) from survivors. With Euclidean as distance measure and SD filtering 
< 0.5, the tumours were joined into one large cluster, together with only one tumour 
from a deceased patient (Figure. 8A). With the corresponding test using Pearson 
correlation coefficient, the tumours were separated into two groups without any 
infiltration of tumours from deceased patients (Figure. 8B). Using SD filtering < 1 and 
Pearson correlation coefficient, 1,312 probes were sorted out, and the 12 tumours 
composed one large cluster together with only one tumour from a deceased patient. This 
result strengthens the theory that there are biological differences between tumours from 
survivors and tumours from deceased patients within this homogeneous, similarly treated 
group. Further analysis of the genes differently expressed among these tumours is of 
importance. 
 
A                B   
 
Figure 8. A) Dendrogram from Average linkage and Euclidean distance analysis (SD > 0.5).  
B) Dendrogram from Average linkage and Pearson correlation coefficient distance analysis 
(SD > 0.5). The tumours in the dendrogram are named with tumour ID, patient status 
(S=Survivor D=Deceased), stage (A, B or C), and 0 for radical surgery. The most recurrent 
groups are marked with squares. 
 
Subsequently, we compared the 12 tumours from patients in the subgroup of survivors 
that clustered together with the 42 remaining tumours with a moderated t test. The 
comparison showed that 204 genes could be classified as significantly differently 
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expressed using our criteria (genes with an adjusted P < 0.05 and at least a twofold change 
between groups). This subgroup of tumours from survivors may represent a subset of 
tumours with a specific genetic signature associated to less aggressive tumour progression 
and/or to tumours more sensitive to chemotherapy treatment. All tumours except one in 
the cluster are highly or moderately differentiated, which strengthens this theory. Further, 
many of the genes are associated with the immune function, which correlate with 
previous findings of immune-related gene expressions up-regulated in long-term survivors 
[75]. This suggests that the immune response is involved in ovarian cancer survival. It is 
possible that an activated immune response helps to defeat the tumour cells, resulting in 
prolonged survival. 
 
When tumours from all survivors were compared with tumours from deceased patients, 
two genes were differently expressed, TACC1 and CDH3. The difference in CDH3 
expression was caused by low or absent intensity values for the tumours and was 
therefore not further evaluated. However, no genes were significantly differently 
expressed between stage IIIa+b and IIIc tumours. Further, the results from our 
comparison of tumours from patients with and without macroscopic residual tumour left 
after primary surgery demonstrated similar expressions in the tumours, since P = 1 for all 
genes, though, we have previously detected cytogenetic differences with CGH for these 
groups. Our results indicate that there are biological differences concerning substage and 
surgical outcome; however, this is not regulated at the gene expression level. The detected 
cytogenetic differences could be a result of tumour progression, which may cause specific 
chromosomal alterations, but is not reflected as changes in gene expressions. 
 
The corresponding analysis with BASE was used to control the data from R, and the 
results correlated well (unpublished data). Further, all genes analysed in downstream 
applications were detected as differently expressed with both BASE and R. 
 
Several groups have used microarray to analyse the gene expression profiles of ovarian 
cancers. Earlier studies compared ovarian cancer and normal ovarian epithelium, and 
tumours with various stage, grade, and histopathology [74, 94, 105-107]. Moreover, 
microarray analyses of ovarian carcinomas concerning survival have identified genes or 
successfully created gene profiles that can distinguish between short- and long-term 
survivors [75, 108-110]. However, in contrast to CGH analysis of ovarian 
adenocarcinomas, there is a limited overlap of data among microarray analyses, owing to 
several factors [111]. First, the number of tumours studied is low and consists of different 
stages and mixtures of histopathological subtypes. Second, different microarray 
technology platforms and statistics are used, and the definition of different endpoints 
varies in the studies. Therefore, external validations of microarray results are required to 
verify if the data are relevant to use. Spentzos et al. [108] used 34 ovarian 
adenocarcinomas and found a 115-gene signature that could distinguish between short- 
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and long-time survivors. This profile worked successfully in an external validation set of 
34 new tumours. Further, Dressman et al. [112] created a model that predicts the 
response to platinum-based therapy, and Hartmann et al [113] developed a 14-gene 
predictive model to distinguish patients with short versus long time to recurrence. The 
predictive models were then evaluated with new tumour samples and the models 
correlated well, indicating that it is possible to predict the clinical outcome with gene 
expression profiles. Such a profile is of interest to create and test with the 204 genes 
found in our study. However, proteins are more stable than mRNA and differences in 
protein expressions may also be relevant to the tumours’ biological properties. Therefore, 
we moved on to analyse if the differences also were detectable at the protein level, 
followed by an external validation of selected genes with QPCR and western blot in a new 
set of tumours.  
 
4.3 Verification and protein analysis 
 
We verified our microarray data with QPCR in 19 tumours and used the results to narrow 
down the number of relevant genes to study at the protein level. The microarray analysis 
revealed 11 genes that were expressed differently in tumours from survivors and from 
deceased patients with an FDR-adjusted P < 0.1 and at least twofold change between the 
groups. The difference in number of genes in Figure 3, paper II, is caused by low or 
absent intensity values for the genes in several tumours, and these genes were excluded. 
Seven genes were selected due to their function and connection to cancer. Four of the 
seven genes, CLU, ITGB3, TACC1, and MUC5B were more expressed in tumours from 
survivors, and three genes, CAPG, PRAME, and TROAP were more expressed in 
tumours from deceased patients.  
 
With microarray, several thousand genes are analysed at the same time. Different 
modifications of the data, such as normalisation, generate questions about the reliability 
of the results. The QPCR data are also affected by normalisation and estimation of the 
efficiency. The QPCR and microarray data were highly correlated (P < 0.01 for all genes), 
and the correlations confirm the accuracy of both methods and assure that the detected 
differences are relevant. Four of the genes analysed, CLU, ITGB3, PRAME, and CAPG 
were differently expressed when measured with QPCR. The lower number of tumours 
included in the QPCR analysis could explain the divergent results compared with the 
microarray results. However, we found that the QPCR analysis required higher mRNA 
quality to get reliable results; therefore, we did not analyse all tumours with this method.  
 
We based our further analysis on the QPCR results, and 43 tumours were analysed with 
western blot for semiquantitative analysis. The differences in expressions between 
tumours from survivors and tumours from deceased patients were also detected at the 
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protein level for CLU, ITGB3, PRAME, and CAPG and were significant for all four 
proteins. Moreover, IHC staining revealed that CLU was not expressed in the nucleus in 
any tumour, which was in agreement with our western blot results. Further, IHC was used 
to ensure that tumour cells expressed ITGB3, since it is also expressed on endothelial 
cells, monocytes, platelets, and megakaryocytes. Positive tumour staining was detected in 
23 of 43 samples. Four of the 20 negative tumour samples were from survivors. In 
addition to the semiquantitative analysis of ITGB3, we performed a chi-square analysis of 
the positive and negative staining and ITGB3 was significantly more expressed in 
tumours from survivors (data not shown).  
 
The differences in protein expressions, and not only gene expressions, indicate that the 
proteins’ function could be involved in tumour growth and progression. The protein CLU 
was expressed as cCLU or sCLU, which is in accordance with previous findings [66, 67]. 
Although CLU expression increases in tumours during progression, its role as a 
biomarker for survival has to be clarified. The expression of cCLU has been associated 
with longer survival in patients with lung cancer, which is in concordance with our results 
[68].  At first, this may seem to be in disagreement with previous findings of increased 
CLU expression in advanced stages. However, we investigated only advanced stage 
disease, and in this group CLU could be a marker for better survival, according to our 
results. In a study of 31 tumours by Lancaster et al. [75], the gene expression of PRAME 
was up-regulated in ovarian cancer samples compared to normal ovarian surface 
epithelium, but was not detected as differently expressed concerning survival. However, 
PRAME expression has been associated with unfavourable outcome for breast cancer 
patients and indicated as an independent prognostic factor for survival [76]. These data 
correlate well with our results, where PRAME was more expressed in tumours from 
deceased patients, and promote the role of PRAME as a prognostic factor for cancer 
patients. CAPG was more expressed in tumours from deceased patients in our study. The 
protein is involved in the control of cell migration, and this function associates up- 
regulation of CAPG with tumour progression, which correlates with our data. The role of 
ITGB3 expression is discussed in the next section, where we continue to estimate the 
significance of the results with an external validation of the gene and protein expressions 
for the four biomarkers. 
 
4.4 External validation 
 
A limitation in many studies of biomarkers, with microarray and other methods, is the 
lack of follow up with external validation of significant findings. We performed an 
external validation of the four genes and proteins in a new set of advanced ovarian serous 
adenocarcinomas, to determine if the differences in expressions are relevant to use as 
prognostic markers. When we compared the gene and protein expressions between 
RESULTS AND DISCUSSION 
33 
tumours from survivors and tumours from deceased patients, ITGB3 was the one found 
as differently expressed. The differences were detected for both the gene and the protein 
expressions, which strengthens the credibility of our results. 
 
The loss of ITGB3 expression in tumours from deceased patients and high expression in 
tumours from survivors may be used as a biomarker for patients with advanced serous 
ovarian tumours. The expression of ITGB3 in ovarian cancer seems to differ compared 
with other tumours. Expression of αvβ3 integrins has been linked to bad prognosis for 
breast cancer and melanoma patients. However, the expression is associated with highly 
differentiated ovarian carcinomas compared to less differentiated tumours [41-44]. In 
contrast to other tissues, the normal ovary continuously regenerates cells during wound 
healing after ovulation, which involves the expression of different cell adhesion 
molecules, such as integrins. The αvβ3 integrins are expressed in normal ovarian 
epithelium and interacts with vitronectin in the ECM (Figure 4) [114]. The ITGB3 
expression in normal ovarian epithelium and its expression in well-differentiated ovarian 
carcinomas may reflect the preservation of normal cell properties. In our study, the 
expression of ITGB3 in tumours from survivors may indicate that these tumour cells still 
retain normal cell properties, and are, therefore, less aggressive.  
 
Once a potential biomarker is detected, it faces a lengthy evaluation before it can be used 
in clinical applications. Our results strongly suggest a prospective evaluation of ITGB3 
expression levels to determine if it is possible to distinguish patients who will respond to 
standard treatment from those who will not. It would also be worth considering a study 
of ITGB3 expression in stage I and stage II serous ovarian tumours, and in other 
histopathological subtypes. In future, it may be that patients who respond to standard 
therapy could be treated with a more moderate combination of anti-cancer agents, and 
higher-risk patients might be offered additional chemotherapy and more frequent follow 
up at an initial state.  
 
The insignificant results for CLU, CAPG, and PRAME in the present study highlight the 
importance of verifying data in external validation sets of tumours, although, the number 
of tumours analysed with QPCR in this study was low, and small groups may have had an 
impact on the results. However, earlier studies have reported CLU as down-regulated and 
CAPG and PRAME as up-regulated in advanced carcinomas compared to early tumours 
or normal tissue [60-62, 69, 70, 84, 85]. Even though we did not detect any differences in 
relation to survival in our analysis, the expressions of CLU, CAPG, and PRAME might 
still be associated with the development and progression of serous ovarian 
adenocarcinomas.  
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4.5 Concordance of results 
 
In an effort to combine the results from the CGH and microarray analysis concerning 
survival, we only found three genes located in frequently altered chromosome regions. 
This finding suggests that chromosome alterations do not directly affect the gene 
expression levels, which is in agreement with previous results of only 8.2% agreement of 
the gene expressions and copy number changes in serous ovarian tumours [115]. Two of 
the differently expressed genes, TACC1 and CLU are located at chromosome 8p, and this 
region was significantly more deleted in tumours from deceased patients than in those 
from survivors. ITGB3, which also was significantly less expressed in tumours from 
deceased patients, is located at 17q21.32. This region is slightly more common as deleted 
in tumours from deceased patients (38% compared to 28% in tumours from survivors). 
 
Eleven of the 12 tumours in the sub group of survivors detected with microarray were 
analysed with CGH. We studied the chromosome regions significantly differently altered 
concerning survival in these tumours. We found that each of chromosome 1q, 4p, 8p, and 
16q was affected once, and each of chromosome 4q, 5q, and X was affected twice in this 
tumour set. These data correlate with the number of changes among all survivors and did 
not present any differences. 
 
We analysed the chromosome regions containing CLU and ITGB3, and the 
corresponding gene and protein expressions with four different methods in 19 tumours. 
The results from the five methods are summarised in Table 1 and 2. The gene and protein 
expressions are in concordance, irrespective of the method used to measure the 
expression levels. The number of chromosome copies seems to have no affect on the 
expression levels. However, loss of chromosome regions were more common disparities 
in our study, and losses detected by CGH probably have less impact on the gene 
expressions than gains and amplifications. The tumour cells might compensate the loss of 
one region with an elevated expression of the genes from the equivalent chromosome 
that still remains in the cell.  
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Table 1 displays the CLU results measured with the different methods. A greyscale shows the 
increase of CLU expression, from white to dark grey. Survivors are marked with grey and 
diagonal lines indicate missing values.  
Tumour 5 year 
survival 
CGH  
8p21-p12  
(copy numbers)
Microarray 
Log2(ratio)
QPCR 
(relative 
expression)
Western blot 
(relative 
expression) 
IHC staining 
in epithelial 
cells  
443 deceased <2 -1.2 0.59 0.30 - 
251 deceased 2 -1.07 -0.05 0.23 + 
124 deceased 2 -0.25 0.71 0.44 + 
1147 deceased 2 -0.21 1.81 0.46 + 
1151 survivor ////NA//// 0.04 0.98 0.24 + 
92 deceased <2 0.32 1.26 0.06 - 
946 survivor <2 0.34 1.11 0.23 - 
1240 deceased >2 0.62 2.57 0.64 + 
68 deceased 2 0.75 3.19 1.40 - 
154 survivor 2 0.75 3.35 0.93 + 
915 deceased 2 1.43 2.37 0.13 + 
247 survivor ////NA//// 1.62 3.72 2.21 - 
1224 deceased <2 1.79 3.73 0.23 + 
903 survivor 2 1.83 4.63 1.45 + 
1125 survivor ////NA//// 2.23 4.51 0.47 + 
139 survivor >2 2.36 4.87 0.39 + 
436 survivor >2 2.79 4.60 0.93 + 
685 deceased <2 2.83 3.66 0.71 + 
1126 survivor 2 3.00 4.48 0.54 + 
 
Table 2 displays the ITGB3 results measured with the different methods. A greyscale shows the 
increase of ITGB3 expression, from white to dark grey. Survivors are marked with grey and 
diagonal lines indicate missing values.  
Tumour 5 year 
survival 
CGH  
17q21.32 
(copy numbers)
Microarray 
Log2(ratio)
QPCR 
(relative 
expression)
Western blot 
(relative 
expression) 
IHC staining 
in epithelial 
cells  
251 deceased 2 0 -2.94 0.04 - 
915 deceased 2 -0.73 -2.59 0.15 - 
685 deceased 2 -0.43 -1.35 0.19 - 
1147 deceased 2 -1.35 -1.14 0.58 - 
68 deceased 2 -1.94 -1.02 0.93 - 
1224 deceased 2 -0.97 -0.61 0.42 - 
1151 survivor ////NA//// -1.47 -0.25 0.76 + 
443 deceased 2 -0.46 -0.19 1.27 - 
946 survivor 2  -0.17 1.07 + 
124 deceased 2 -0.34 -0.04 0.24 + 
247 survivor ////NA//// -1.11 0.11 0.73 - 
92 deceased 2 0.2 0.14 0.09 + 
1240 deceased 2 -0.33 0.46 0.28 + 
154 survivor 2 //NA/// 0.51 0.31 - 
1126 survivor <2 0.24 0.68 0.50 + 
139 survivor 2 1.05 2.27 3.35 + 
436 survivor >2 3.02 3.37 2.27 + 
1125 survivor ////NA//// //NA/// 3.51 0.34 + 
903 survivor 2 3.55 5.57 1.69 + 
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5 CONCLUDING REMARKS 
 
Taken together, we have found cytogenetic changes and differences in gene and protein 
expressions that support the theory that there are detectable biological differences 
between advanced ovarian adenocarcinomas from survivors and deceased patients within 
a clinically and histologically homogeneous group. These differences indicate that it is 
possible to predict the clinical outcome with a biological model for ovarian cancer 
patients. The main results can be summarised as follows: 
 
• There are cytogenetic differences in relation to survival, surgical outcome and tumour 
substage. Gain of regions at chromosome 1 and loss of regions at chromosome 4, 5, 8, 
16, and X are common disparities associated with reduced survival for patients with 
ovarian cancer. 
 
• There are differences in gene expressions in tumours from survivors and tumours from 
deceased patients. A detected cluster with 60% (12/20) of survivors may represent a 
subset of tumours with a specific genetic signature associated to less aggressive tumour 
progression and/or to tumours more sensitive to chemotherapy treatment. 
 
• The loss of ITGB3 expression in tumours from deceased patients and high expression 
in tumours from survivors could be used as a biomarker for patients with advanced 
serous tumours. 
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